

Antineoplastic Therapy and Immunotherapy Course

Day One: Monday, February 6, 2023, Herberman 201 AB

Day Two: Monday, February 13, 2023, Herberman 201 AB

Day Three: Monday, February 20, 2023, Herberman 201 AB

Day Four: Monday, March 6, 2023, Herberman 201 AB

Test Date: Tuesday March 14, 2023 Remote

UPMC Hillman Cancer Center

On site attendance option for staff who work on Shadyside Campus, all other staff will attend remotely

via Microsoft TEAMS

Learning Objectives

After participation in this activity, the learner will be able to:

- Discuss the expectations related to class content and the participant's professional responsibilities
- Discuss the roles of antineoplastic therapy and immunotherapy in the treatment of cancer
- Recall the pharmacology of different classes of antineoplastic and supportive therapies
- Recognize side effects and organ toxicities that patients may experience while receiving antineoplastic and supportive therapies
- Discuss management strategies for patients receiving antineoplastic and supportive therapies, including the prevention and treatment of toxicities and side effects
- Describe the safe administration of antineoplastic and supportive therapies
- Identify interventions to prevent chemotherapy errors
- Develop a patient care management plan for a patient receiving antineoplastic therapies and supportive therapies
- Identify three resources for oncology healthcare providers to utilize
- Demonstrate that learning has occurred by achieving at least an 80% on the final exam

Agenda

Day 1: Monday, February 6, 2023

8:00 am	Course Overview	Lynne O'Connor, MSN, RN
8:15 am	Genetics vs. Genomics	Melissa K. Bourdus, MS, CGC
8:50 am	Alkylating Agents	Trish Seaman, MSN, RN, CMSRN
10:15 am	Break	
10:25 am	Tyrosine Kinase Inhibitors: Part One	Amanda Agnew, PharmD, BCOP
11:10 am	Tyrosine Kinase Inhibitors: Part Two	Jason Steele, PharmD, BCOP
12:05 pm	Lunch	
12:45 pm	Principles of Antineoplastic Drug Therapy	Ernie Sanchez, PharmD
1:35 pm	Oral Adherence	Nancy Birus, RN, OCN
2:10 pm	Break	
2:20 pm	Antimetabolites	Tim George, PharmD, BCOP
3:30 pm	Adjournment	Lynne O'Connor MSN, RN

Agenda

Day 2: Monday, February 13, 2023

8:00 am	Welcome	Lynne O'Connor, MSN, RN
8:05 am	Antitumor Antibiotics	Brian Miller, PharmD
9:20 am	Cytokines, L Asparaginase, and Vaccine Therapy	Tim George, PharmD, BCOP
10:15 am	Break	
10:25 am	Administration	Markie Rearick, MSN, RN, BMTCN
11:40 am	Hormone Therapy: Breast Cancer	Courtney Stetor, MPAS PA-C
12:00 pm	Hormone Therapy: Prostate	Tom Boyer PA-C
12:30 pm	Lunch	
1:10 pm	Organ Toxicities	Linda Pfeifer, CRNP, RN
2:20 pm	Extravasations	Nancy Birus, RN, OCN
3:05 pm	Break	
3:15 pm	CAR-T Therapy	Shrina Duggal, PharmD, BCOP
4:10 pm	Adjournment	Lynne O'Connor MSN, RN

Agenda

Day 3: Monday, February 20, 2023

8:00 am	Welcome	Lynne O'Connor, MSN, RN
8:05 am	Monoclonal Antibodies: Part 1	Melissa Bastacky, PharmD, BCOP
9:10 am	Monoclonal Antibodies: Part 2	Melissa Bastacky, PharmD, BCOP
10:05 am	Growth Factors	Jaime Kriner, PA-C
10:50 am	Break	
11:00 am	Protectants	Lynne O'Connor, MSN, RN
11:30 am	Hypersensitivity	Alyssa Owens, MPAS, PA-C
12:20 pm	Lunch	
1:05 pm	Miscellaneous Agents	Tim Brenner, PharmD, BCOP
2:35 pm	Break	
2:45 pm	Error Prevention	Amy DiMaggio, MSN, RN, CMSRN, OCN
3:20 pm	Adjournment	Lynne O'Connor, MSN, RN

Agenda

Day 4: Monday March 6, 2023

8:00 am	Welcome	Lynne O'Connor, MSN, RN
8:05 am	Plant Alkaloids	Nicole Kahler, DNP, CRNP, AOCNP
9:20 am	Homework Review	Lynne O'Connor, MSN, RN
9:50 am	Break	
10:00 am	Case Study	Brittini Prosdocimo, MSN, RN, BMTCN
10:30 am	Review/Jeopardy	Amy DiMaggio, MSN, RN, CMSRN, OCN Lynne O'Connor, MSN, RN Brittini Prosdocimo, MSN, RN, BMTCN
12:00 pm	End of Class/Adjournment	Lynne O'Connor, MSN, RN

Course Exam

UPMC Employees:

You will take course exam on your business unit as specified by your manager. The electronic test will be taken virtually in HR Direct - Learning on Tuesday, March 14, 2023. The following information must be provided to course director by **Monday, February 20th, 2023 (Day 3) via email to Lynne O'Connor at OConnorLJ@upmc.edu**

- Name of exam proctor and contact information
- Test date (if other than scheduled test date)

Non-UPMC Attendees:

You will complete a paper test at your business unit as directed by your manager on the same day as the UPMC employees. The following information must be provided to course director by Monday, **February 20th 2023 (Day 3) via email to Lynne O'Connor at OConnorLJ@upmc.edu**

- Name of exam proctor and contact information
- Test date (if other than scheduled test date)

Faculty Listing

*Amanda Agnew, PharmD, BCPS,
BCOP
Clinical Oncology Pharmacist
UPMC Hillman Cancer Center*

*Melissa K. Bourdius, MS, CGC
Genetics Counselor
Special Genetic Counsel
UPMC Magee-Womens Hospital*

*Amy DiMaggio, MSN, RN, CMSRN,
OCN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Nicole Kahler, DNP, CRNP, AOCNP
Nurse Practitioner
University of Pittsburgh Physicians*

*Lynne O'Connor, MSN, RN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Brittni Prosdocimo, MSN, RN, BMTCN
Advanced Clinical Education Specialist
UPMC Hillman Cancer Center*

*Trish Seaman, MSN, RN, CMSRN
Nurse Educator, Central PA
UPMC Hillman Cancer Center*

*Melissa Bastacky, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Tom G. Boyer, PA-C
Physician Assistant
University of Pittsburgh Physicians*

*Shrina Duggal, PharmD, BCOP
Lead Clinical Oncology Pharmacist
UPMC Hillman Cancer Center*

*Jaime Kriner, PA-C
Director, APP Relations
UPMC Hillman Cancer Center*

*Alyssa Owens, MPAS, PA-C
Physician Assistant
UPMC Hillman Cancer Center*

*Markie Rearick, MSN, RN, BMTCN
Clinical Education Specialist
UPMC Shadyside*

*Jason Steele, PharmD, BCOP
Oncology Clinical Pharmacist
UPMC Hillman Cancer Center*

*Nancy Birus RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Tim Brenner, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Timothy George, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Brian Miller, PharmD
Manager, Investigational Drug
Services Pharmacy
UPMC Hillman Cancer Center*

*Linda Pfeifer, CRNP, RN
Nurse Practitioner
UPMC Hillman Cancer Center*

*Ernest M. Sanchez, Pharm.D.
Lead Pharmacist of Oncology
Operations, Department of
Pharmacy
UPMC Shadyside Hospital*

*Courtney Stetor, MPAS PA-C
Physician Assistant
UPMC Hillman Cancer Center*

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 25.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 25.25 contact hours.

To receive 25.25 Contact Hours, the learner must sign into each class, attend the entire activity, each class day submit roster for each day or sign roster electronically in meeting. Evaluation will be completed on CCE website after passing the test.

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following information was provided:

Amanda Agnew, Melissa Bastacky, Nancy Birus, Melissa K. Bourdus, Thomas G. Boyer, Timothy Brenner, Amy DiMaggio, Shrina Duggal, Timothy George, Nicole Kahler, Jaime Kriner, Brian Miller, Lynne O'Connor, Alyssa Owens, Linda Pfeifer, Markie Rearick, Brittni Prosdocimo, Ernest Sanchez, Trish Seaman, Jason Steele, Courtney Stetor, and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.